These results in combination with our current findings showing increased TNFR1 expression in progressing OPMD samples is suggestive of a potential therapeutic target and is the first time that TNFα/TNFR1 signaling has been demonstrated to be elevated in progressing OPMDs. The gene discussed is TNFRSF1A; the disease is oculopharyngeal muscular dystrophy.